Straumann Holding Ag · SIX:STMN
Straumann — Q3 2022 Earnings Presentation
13 slides from Straumann's earnings presentation, Nov 5, 2022
Slide 1: Third-quarter 2022 report
01.11.2022 Third-quarter 2022 report Webcast for investors, analysts and media Basel, November 02, 2022 1 Disclaimer This presentation contains forward-looking statements that reflect the current views of management, and which are subject to known and unknown risks, uncertainties and other factors t
Slide 2: Agenda
01.11.2022 Agenda Highlights Guillaume Daniellot Business and regional review Peter Hackel Recent achievements and strategy in action Guillaume Daniellot Outlook 2022 Guillaume Daniellot Guillaume Daniellot Q&A and upcoming events Peter Hackel 3 Highlights Guillaume Daniellot, CEO 4 2
Slide 3: Strong third quarter with 12% organic revenue growth
01.11.2022 Strong third quarter with 12% organic revenue growth THIRD QUARTER REVENUE ORGANIC GROWTH1 QUALITY OF SOLUTIONS CHF 551 million 12.2% Roxolid SLActive Nine-month: CHF 1.7 billion Nine-month: 18.0% Study to demonstrate surface superiority nine-month: 250bps currency headwind DIGITAL TRANSF
Slide 4: Market size in CHF bn
01.11.2022 CHF 18 billion addressable market 6 5.3 4.8 5 4 Market size in CHF bn 2.6 2.6 3 2.1 2 0.7 1 <15% >45% <5% <5% <5% >10% 0 Premium Implant Value Implant Clear Aligners Biomaterial Custom CadCam prosthetics equipment 7 Source: Straumann Group estimates 2021 7 Business and regional review Pet
Slide 5: Strong revenue development in the first nine months
01.11.2022 Strong revenue development in the first nine months Revenue development (in CHF million, rounded) Regional share of 17% organic growth in CHF 35 1′729 33 56 13% LATAM 140 12% APAC 18% organic 21% NAM 1′482 16 1′466 -32 Change in organic growth 53% EMEA 23% 12% 11% 35% Revenue FX effect M&
Slide 6: Asia Pacific with solid and LATAM leading growth
01.11.2022 Asia Pacific with solid and LATAM leading growth Asia Pacific Revenue change (organic) 74.4% ▪ Revenue in China still 62.8% 56% impacted by local COVID lockdowns 19% of Group* 28.5% ▪ Strong performance in 17.9% 17.0% 18.4% Australia, Taiwan and Japan 5.9% 8.6% ▪ Chinese authorities appro
Slide 7: Implant Roxolid SLActive study highlights performance
01.11.2022 Recent achievements & strategy in action Guillaume Daniellot, CEO 13 Implant Roxolid SLActive study highlights performance Competitor Replica BLX Crestal bone level at 8 weeks Best results: combination of BLX geometry and Roxolid SLActive 14 14 7
Slide 8: Further investment in digital by investing in SmileCloud
01.11.2022 Promotional activities in full swing European Association Osseointegration (EAO) Neodent Zi implant launch 15 15 Further investment in digital by investing in SmileCloud Smile design Clinical collaboration platform Interdisciplinary planning to improve case acceptance to share cases with
Slide 9: New ClearCorrect software release: ClearPilot 5.0
01.11.2022 New ClearCorrect software release: ClearPilot 5.0 Bolton analysis ▪ Analysis tools ▪ Bolton analysis tables / charts ▪ Tooth movement assessment ▪ Collision values monitoring and alerts ▪ Editing enhancements ▪ Multiple tooth grouping / editing ▪ Compass tooth editing ▪ Compass multi-toot
Slide 10: Outlook 2022
01.11.2022 Dr Smile – our leading brand in Europe for doctor- led clear aligner treatment 19 19 Outlook 2022 20 10
Slide 11: Outlook 2022 raised
01.11.2022 Outlook 2022 raised ▪ Patient demand for the Group solutions remains good Market ▪ Macro-economic challenges continue to influence regions environment differently ▪ Group aims to achieve organic revenue growth in the mid-teens Our revenue versus the strong comparative year and ▪ Profitabi
Slide 12: Straumann Group's currency exposure
01.11.2022 Calendar of upcoming events 2022 Event Location 4 November ZKB Swiss Equity Conference Zurich 8 - 10 November J.P. Morgan Roadshow Chicago, Toronto, Montreal 16 November Credit Suisse Equity Forum Switzerland Zurich 9 December Mirabaud Roadshow Geneva 2023 Event Location 21 February Full-
Slide 13: Thank you
01.11.2022 Thank you 25 13